EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 58 Pages
|EVP-6124(精神分裂症治療藥):市場預測與分析 EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022|
|出版日期: 2014年02月28日||內容資訊: 英文 58 Pages||
EVP-6124是小分子型a7尼古丁性乙醯膽鹼受體(nAChR)受體激動劑，現在由EnVivo和三菱田邊製藥共同開發中。目前正在研究將a7 nAChR的刺激作用應用在許多神經障礙(老年癡呆症，尼古丁依賴症等)治療法上。這是因為這個刺激作用具有緩和目標的腦神經炎症障礙途徑的可能性，(Tracey, 2007)便是這個研究的結果。EVP-6124是以3-(1-methylpyrrolidin-2-yl)吡啶知名的口服藥法，由於其強力的親油性而可滲入中樞神經。這個藥劑可作為乙醯膽鹼(ACh)受體的共同受體激動劑，此外因為增加了敏感性，而可使微量的ACh也能維持一般認知機能。由於EVP-6124はa7有選擇性，對a4ß2亞基不起反應，這表示它可說毫無成癮性。
Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.
EVP-6124 is a small-molecule a7 nicotinic acetylcholine receptor (nAChR) agonist in co-development by EnVivo and Mitsubishi Tanabe. a7 nAChR stimulation is being researched as a therapy for several neurological conditions, including larger indications such as Alzheimer's disease and nicotine dependence, following the observation that the target may modulate neuroinflammatory pathways in the brain (Tracey, 2007). Also known as 3-(1-methylpyrrolidin-2-yl) pyridine, EVP-6124 is an oral medication that penetrates the CNS easily due to its strong lipophilicity. It acts as a co-agonist and sensitizes the ACh receptors so that lesser amounts of ACh can preserve normal cognitive functioning. EVP-6124 is a7-selective and does not activate the a4ß2 subunit, meaning it is non-addictive.